• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Evaluation of no evidence of progression ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1002/ana.25313
PMID :
30155979
Permalink :
http://hdl.handle.net/20.500.12210/4500
Title :
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
Author(s) :
Wolinsky Jerry, S [Auteur]
Montalban, Xavier [Auteur]
Hauser Stephen, L [Auteur]
Giovannoni, Gavin [Auteur]
Vermersch, Patrick [Auteur] refId
Lille Inflammation Research International Center - U 995 [LIRIC]
Bernasconi, Corrado [Auteur]
Deol-Bhullar, Gurpreet [Auteur]
Garren, Hideki [Auteur]
Chin, Peter [Auteur]
Belachew, Shibeshih [Auteur]
Kappos, Ludwig [Auteur]
Journal title :
Annals of neurology
Abbreviated title :
Ann. Neurol.
Publication date :
2018-08-29
ISSN :
1531-8249
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
OBJECTIVE: No evidence of progression or active disease (NEPAD) is a novel combined endpoint defined by the absence of both progression and inflammatory disease activity in primary progressive multiple sclerosis (PPMS). ...
Show more >
OBJECTIVE: No evidence of progression or active disease (NEPAD) is a novel combined endpoint defined by the absence of both progression and inflammatory disease activity in primary progressive multiple sclerosis (PPMS). In the placebo-controlled phase III ORATORIO study (NCT01194570), we investigated the effect of ocrelizumab on this comprehensive outcome and its components in a post-hoc analysis. METHODS: The proportion of patients with NEPAD (no evidence of progression [NEP; no 12-week confirmed progression of >/=1/>/=0.5 points on the Expanded Disability Status Scale if the baseline score was </=5.5/>5.5 points, respectively; no 12-week confirmed progression of >/=20% on the Timed 25-Foot Walk test and 9-Hole Peg Test], no brain magnetic resonance imaging activity [no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions], and no protocol-defined relapse) from baseline to week 120 was determined in ocrelizumab- (600 mg; n = 465) and placebo-treated (n = 234) patients. RESULTS: The majority of ORATORIO study patients with PPMS experienced clinical progression or evidence of disease activity. From baseline to week 120, 29.9% and 42.7% ocrelizumab-treated compared to 9.4% and 29.1% placebo-treated patients maintained NEPAD (relative risk [95% confidence interval {CI}], 3.15 [2.07-4.79]; p < 0.001) and NEP (relative risk [95% CI], 1.47 [1.17-1.84]; p < 0.001), respectively. Effects on the individual components of both measures were consistent with the compound outcomes. INTERPRETATION: Compared to placebo, ocrelizumab enhanced 3-fold the proportion of PPMS patients with no evidence of either progression or inflammatory disease activity. NEPAD may represent a sensitive and meaningful comprehensive measure of disease control in patients with PPMS. Ann Neurol 2018;84:527-536.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Collections :
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Research team(s) :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Submission date :
2019-03-01T14:08:00Z
Université de Lille

Mentions légales
Université de Lille © 2017